However, few selective and potent inhibitors of eEF2K have been identified thus far due to weak (e.g., A‐484954) or non‐selective inhibition of eEF2K (e.g., NH125).[6] Therefore, identification of highly effective and specific small molecules targeting eEF2K may help develop novel therapeutic agents against cancer.[7]. This evidence concerns the gene EEF2K and cancer.